nicotine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1920 54-11-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nicotine
  • L-Nicotine
  • (S)-Nicotine
  • (-)-Nicotine
  • nicotine bitartrate anhydrous
  • nicotine polacrilex
Devices or delivery systems used to aid in ending a TOBACCO habit.
  • Molecular weight: 162.24
  • Formula: C10H14N2
  • CLOGP: 0.88
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 16.13
  • ALOGS: -0.24
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg Chewing gum
60 mg Inhal
30 mg N
30 mg SL
14 mg TD

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 16.70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.52 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.95 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 7, 1991 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 541.27 13.13 101 14640 535 53333790
Drug withdrawal syndrome neonatal 278.99 13.13 73 14668 2077 53332248
Drug dependence 256.29 13.13 123 14618 21349 53312976
Macular degeneration 241.42 13.13 100 14641 12261 53322064
Foetal exposure during pregnancy 208.55 13.13 126 14615 34589 53299736
Incorrect product administration duration 207.63 13.13 86 14655 10538 53323787
Premature delivery 205.52 13.13 113 14628 25991 53308334
Product adhesion issue 173.33 13.13 63 14678 5434 53328891
Overdose 170.84 13.13 178 14563 107558 53226767
Maternal exposure during pregnancy 145.10 13.13 196 14545 155443 53178882
Myocardial stunning 100.56 13.13 20 14721 155 53334170
Intentional product misuse 84.29 13.13 85 14656 49307 53285018
Application site erythema 82.17 13.13 36 14705 5055 53329270
Jaundice neonatal 80.30 13.13 23 14718 921 53333404
Accidental overdose 80.24 13.13 58 14683 21421 53312904
Dependence 76.78 13.13 27 14714 2114 53332211
Application site pruritus 72.39 13.13 31 14710 4118 53330207
Necrosis ischaemic 68.93 13.13 20 14721 839 53333486
Rhesus incompatibility 67.29 13.13 13 14728 85 53334240
Drug abuse 66.26 13.13 86 14655 65440 53268885
Exposure during pregnancy 65.59 13.13 121 14620 124739 53209586
Poor feeding infant 64.80 13.13 15 14726 252 53334073
Premature baby 63.96 13.13 49 14692 19752 53314573
Rheumatoid arthritis 62.49 13.13 7 14734 314524 53019801
Product quality issue 61.85 13.13 63 14678 36960 53297365
Pneumonia streptococcal 58.54 13.13 21 14720 1742 53332583
Oligohydramnios 55.33 13.13 29 14712 6047 53328278
Beta haemolytic streptococcal infection 52.08 13.13 20 14721 2007 53332318
Maternal exposure during breast feeding 51.40 13.13 23 14718 3394 53330931
Tobacco abuse 46.47 13.13 14 14727 670 53333655
Low birth weight baby 45.92 13.13 26 14715 6311 53328014
Rib deformity 43.03 13.13 10 14731 171 53334154
Chronic obstructive pulmonary disease 42.34 13.13 67 14674 61006 53273319
Exposure via breast milk 42.17 13.13 16 14725 1554 53332771
Treatment noncompliance 39.20 13.13 47 14694 32988 53301337
Application site rash 36.92 13.13 17 14724 2679 53331646
Congenital tricuspid valve incompetence 36.84 13.13 8 14733 99 53334226
Application site reaction 36.50 13.13 12 14729 765 53333560
Anxiety 34.47 13.13 126 14615 196578 53137747
Congenital pulmonary hypertension 33.33 13.13 7 14734 73 53334252
Substance abuse 31.38 13.13 18 14723 4476 53329849
Reversible cerebral vasoconstriction syndrome 30.26 13.13 14 14727 2231 53332094
Developmental hip dysplasia 30.20 13.13 12 14729 1318 53333007
Premature separation of placenta 29.47 13.13 13 14728 1854 53332471
Toxicity to various agents 29.13 13.13 129 14612 219469 53114856
Agitation neonatal 28.30 13.13 9 14732 516 53333809
Caesarean section 28.05 13.13 29 14712 17291 53317034
Maternal drugs affecting foetus 27.89 13.13 18 14723 5528 53328797
Dysmetropsia 27.57 13.13 6 14735 75 53334250
Loss of proprioception 26.90 13.13 8 14733 366 53333959
Fatigue 26.61 13.13 108 14633 730398 52603927
Alopecia 26.52 13.13 16 14725 234567 53099758
Application site irritation 26.30 13.13 12 14729 1852 53332473
Axonal neuropathy 25.95 13.13 10 14731 1013 53333312
Nasal obstruction 25.40 13.13 10 14731 1072 53333253
Xanthogranuloma 25.11 13.13 4 14737 6 53334319
Reversible airways obstruction 24.86 13.13 10 14731 1134 53333191
Throat clearing 24.85 13.13 10 14731 1135 53333190
Arthropathy 23.84 13.13 5 14736 141448 53192877
Application site swelling 23.53 13.13 8 14733 566 53333759
Abnormal dreams 23.31 13.13 21 14720 10580 53323745
Off label use 23.26 13.13 61 14680 472151 52862174
Symphysiolysis 23.24 13.13 4 14737 12 53334313
Premature labour 22.41 13.13 22 14719 12340 53321985
Drug intolerance 21.87 13.13 15 14726 205478 53128847
Application site dermatitis 21.59 13.13 6 14735 215 53334110
Abortion induced 21.00 13.13 20 14721 10806 53323519
Joint swelling 20.23 13.13 21 14720 234617 53099708
Pain 20.14 13.13 89 14652 588309 52746016
Irritability 20.13 13.13 33 14708 30920 53303405
Respiratory failure 19.83 13.13 67 14674 100445 53233880
Cardiac death 19.80 13.13 7 14734 556 53333769
Application site vesicles 19.15 13.13 9 14732 1485 53332840
Treatment failure 18.85 13.13 6 14735 128397 53205928
Pre-eclampsia 18.75 13.13 17 14724 8630 53325695
Therapeutic product effect decreased 18.22 13.13 6 14735 125649 53208676
Systemic lupus erythematosus 18.16 13.13 6 14735 125408 53208917
Oophoritis 18.10 13.13 4 14737 54 53334271
Drug screen positive 18.08 13.13 12 14729 3860 53330465
Arthralgia 17.92 13.13 62 14679 439721 52894604
Nightmare 17.46 13.13 23 14718 17728 53316597
Withdrawal syndrome 17.44 13.13 24 14717 19277 53315048
Application site pain 17.24 13.13 12 14729 4171 53330154
Prinzmetal angina 17.22 13.13 7 14734 816 53333509
Selective eating disorder 16.85 13.13 9 14732 1949 53332376
Megacolon 16.81 13.13 9 14732 1957 53332368
Foetal distress syndrome 16.76 13.13 8 14733 1367 53332958
Application site burn 16.69 13.13 7 14734 883 53333442
Loss of consciousness 16.58 13.13 69 14672 114143 53220182
Application site scar 16.40 13.13 5 14736 249 53334076
Tobacco poisoning 16.13 13.13 4 14737 91 53334234
Sneezing 15.98 13.13 20 14721 14652 53319673
Schizoaffective disorder 15.95 13.13 9 14732 2168 53332157
Full blood count abnormal 15.75 13.13 11 14730 3844 53330481
False positive investigation result 15.50 13.13 6 14735 615 53333710
Foetal growth restriction 15.36 13.13 14 14727 7160 53327165
Suicidal ideation 15.32 13.13 44 14697 60467 53273858
Drug abuser 15.28 13.13 10 14731 3143 53331182
Patent ductus arteriosus 15.10 13.13 11 14730 4107 53330218
Tobacco interaction 14.78 13.13 3 14738 26 53334299
Pyrexia 14.37 13.13 60 14681 403133 52931192
Contraindicated product administered 14.29 13.13 10 14731 135619 53198706
Nervousness 14.27 13.13 28 14713 30150 53304175
Infection 14.18 13.13 16 14725 172189 53162136
Gastric dilatation 13.69 13.13 6 14735 842 53333483
Plethysmography 13.68 13.13 3 14738 39 53334286
Application site warmth 13.67 13.13 4 14737 173 53334152
Drug withdrawal syndrome 13.25 13.13 26 14715 27996 53306329
Hallucination, synaesthetic 13.22 13.13 3 14738 46 53334279

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 380.93 13.47 77 12154 461 32500834
Drug withdrawal syndrome neonatal 286.05 13.47 89 12142 3475 32497820
Drug dependence 270.32 13.47 145 12086 23339 32477956
Incorrect product administration duration 228.67 13.47 79 12152 4299 32496996
Foetal exposure during pregnancy 213.26 13.47 153 12078 41148 32460147
Intentional product misuse 166.70 13.47 125 12106 35926 32465369
Accidental overdose 136.42 13.47 87 12144 19252 32482043
Overdose 130.40 13.47 162 12069 86915 32414380
Product adhesion issue 121.15 13.47 38 12193 1521 32499774
Maternal exposure during breast feeding 102.98 13.47 34 12197 1606 32499689
Premature baby 96.34 13.47 69 12162 18449 32482846
Low birth weight baby 74.29 13.47 41 12190 6953 32494342
Dependence 70.82 13.47 24 12207 1229 32500066
Jaundice neonatal 68.28 13.47 23 12208 1156 32500139
Alcohol abuse 66.94 13.47 33 12198 4439 32496856
Exposure via breast milk 62.30 13.47 24 12207 1778 32499517
Toxicity to various agents 61.51 13.47 176 12055 177865 32323430
Foetal disorder 60.79 13.47 19 12212 751 32500544
Tobacco poisoning 53.15 13.47 9 12222 15 32501280
Neutropenia neonatal 50.82 13.47 16 12215 648 32500647
Drug abuser 48.52 13.47 26 12205 4158 32497137
Drug screen positive 48.19 13.47 26 12205 4215 32497080
Alcohol interaction 46.95 13.47 21 12210 2268 32499027
Tremor neonatal 44.53 13.47 13 12218 406 32500889
Poor feeding infant 42.49 13.47 13 12218 478 32500817
Body temperature abnormal 37.05 13.47 12 12219 533 32500762
Foetal distress syndrome 35.86 13.47 14 12217 1075 32500220
Application site pruritus 35.85 13.47 15 12216 1378 32499917
Substance abuse 35.84 13.47 26 12205 7081 32494214
Breech presentation 35.33 13.47 9 12222 166 32501129
Drug abuse 34.35 13.47 86 12145 80157 32421138
Tobacco abuse 31.93 13.47 10 12221 398 32500897
Drug use disorder 29.84 13.47 18 12213 3603 32497692
Withdrawal syndrome 29.23 13.47 29 12202 12093 32489202
Off label use 29.08 13.47 44 12187 306276 32195019
Application site erythema 28.40 13.47 15 12216 2328 32498967
Schizophrenia 28.08 13.47 26 12205 9958 32491337
Laryngeal dysplasia 27.54 13.47 4 12227 0 32501295
Application site reaction 26.95 13.47 9 12222 440 32500855
Agitation neonatal 25.48 13.47 11 12220 1091 32500204
Tobacco user 25.09 13.47 9 12222 546 32500749
Drug withdrawal syndrome 24.53 13.47 34 12197 20197 32481098
Product quality issue 24.34 13.47 33 12198 19200 32482095
Tachycardia 23.26 13.47 74 12157 79014 32422281
Venolymphatic malformation 23.24 13.47 5 12226 42 32501253
Application site rash 21.42 13.47 9 12222 835 32500460
Treatment noncompliance 20.82 13.47 37 12194 27165 32474130
Acne infantile 20.18 13.47 5 12226 82 32501213
Diarrhoea 19.62 13.47 71 12160 364731 32136564
Renal hypoplasia 19.54 13.47 5 12226 94 32501201
Application site scar 19.11 13.47 4 12227 29 32501266
Renal impairment 18.12 13.47 6 12225 91966 32409329
Pulmonary valve stenosis congenital 17.48 13.47 5 12226 145 32501150
Application site vesicles 17.29 13.47 7 12224 591 32500704
Myoclonic epilepsy 17.01 13.47 8 12223 970 32500325
Weight decrease neonatal 16.85 13.47 6 12225 356 32500939
Breathing-related sleep disorder 16.39 13.47 5 12226 182 32501113
Anxiety 15.99 13.47 75 12156 95930 32405365
Palpitations 15.84 13.47 39 12192 35930 32465365
Application site urticaria 15.74 13.47 4 12227 73 32501222
Antipsychotic drug level increased 15.70 13.47 12 12219 3534 32497761
Euphoric mood 15.45 13.47 14 12217 5213 32496082
Application site discolouration 15.20 13.47 5 12226 233 32501062
Application site pain 15.09 13.47 9 12222 1765 32499530
Drug tolerance increased 15.07 13.47 6 12225 485 32500810
Insomnia 14.99 13.47 76 12155 100272 32401023
Necrotising ulcerative gingivostomatitis 14.95 13.47 4 12227 90 32501205
Death 14.83 13.47 84 12147 382433 32118862
Knee deformity 14.47 13.47 6 12225 539 32500756
Nightmare 14.30 13.47 21 12210 13145 32488150
Neonatal disorder 14.11 13.47 7 12224 954 32500341
Emphysema 14.10 13.47 18 12213 9879 32491416
Potentiating drug interaction 14 13.47 13 12218 4995 32496300
Left ventricular hypertrophy 13.95 13.47 15 12216 6865 32494430
Facial asymmetry 13.89 13.47 5 12226 306 32500989
Rhesus incompatibility 13.76 13.47 3 12228 27 32501268
Maternal drugs affecting foetus 13.73 13.47 12 12219 4265 32497030

Pharmacologic Action:

SourceCodeDescription
ATC N07BA01 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
DRUGS USED IN ADDICTIVE DISORDERS
Drugs used in nicotine dependence
FDA CS M0014836 Nicotine
MeSH PA D018678 Cholinergic Agents
MeSH PA D018679 Cholinergic Agonists
MeSH PA D005731 Ganglionic Stimulants
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018722 Nicotinic Agonists
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D000077444 Smoking Cessation Agents
FDA EPC N0000175706 Cholinergic Nicotinic Agonist
CHEBI has role CHEBI:22917 botanical insecticides
CHEBI has role CHEBI:35471 psychopharmaceuticals
CHEBI has role CHEBI:35474 minor tranquilisers
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:47958 muscarinic agonists
CHEBI has role CHEBI:49110 peripheral nervous system agent
CHEBI has role CHEBI:50846 Biomodulator
CHEBI has role CHEBI:50905 teratogen
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:52290 mitogens
CHEBI has role CHEBI:59163 biological marker
CHEBI has role CHEBI:76924 plant metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Nicotine dependence indication 56294008 DOID:0050742
Smoking cessation assistance indication 384742004
Pellagra indication 418186002 DOID:8457
Niacin deficiency indication 418279001
Nicotine Withdrawal Symptoms indication
Hyperlipidemia off-label use 55822004 DOID:1168
Hypophosphatemia contraindication 4996001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Esophagitis contraindication 16761005 DOID:11963
Myocardial infarction contraindication 22298006 DOID:5844
Hyperthyroidism contraindication 34486009 DOID:7998
Temporomandibular joint disorder contraindication 41888000
Low blood pressure contraindication 45007003
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Thromboangiitis obliterans contraindication 52403007 DOID:12918
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Prinzmetal angina contraindication 87343002
Gout contraindication 90560007 DOID:13189
Magnetic resonance imaging contraindication 113091000
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Arterial hemorrhage contraindication 234003006
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Pheochromocytoma contraindication 302835009
Acute coronary syndrome contraindication 394659003
Pharyngitis contraindication 405737000 DOID:2275
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000
Life-Threatening Cardiac Arrhythmias contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.05 Basic
pKa2 3.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel AGONIST Ki 8.56 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily D member 3 Ion channel IC50 7.40 WOMBAT-PK
Cytochrome P450 2A6 Enzyme IC50 5.36 WOMBAT-PK
Transient receptor potential cation channel subfamily A member 1 Ion channel ACTIVATOR EC50 4.80 IUPHAR
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 5.95 WOMBAT-PK
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 7.85 WOMBAT-PK
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 7.64 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel Ki 4.15 CHEMBL
Acetylcholine receptor; alpha1/beta1/delta/gamma Ion channel Ki 5.83 CHEMBL
Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 Ion channel IC50 7.07 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.68 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel IC50 7.35 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 5.39 WOMBAT-PK
Acetylcholine-binding protein Unclassified Ki 7.20 CHEMBL
Acetylcholine receptor subunit delta Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 9.03 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.89 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.61 CHEMBL
Neuronal acetylcholine receptor subunit alpha-9 Ion channel Kd 8.30 CHEMBL
Neuronal acetylcholine receptor subunit beta-4 Ion channel Ki 7.14 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel Ki 7.33 CHEMBL
Neuronal acetylcholine receptor subunit alpha-2 Ion channel Ki 7.92 CHEMBL
Soluble acetylcholine receptor Unclassified Ki 7.52 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.64 CHEMBL
Lycopene cyclase Enzyme IC50 5.32 CHEMBL
Nicotinic acetylcholine receptor alpha 5 subunit Ion channel Ki 5.61 CHEMBL
Acetylcholine receptor subunit beta-like 2 Ion channel Ki 5.57 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 8.72 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel IC50 8.15 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 6.70 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel Kd 9.40 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor Ion channel Kd 11 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Acetylcholine receptor Ion channel Ki 5.20 CHEMBL
Muscarinic acetylcholine receptor GPCR IC50 4.55 CHEMBL
Transient receptor potential cation channel subfamily A member 1 Ion channel EC50 5 CHEMBL
Potassium voltage-gated channel subfamily D member 3 Ion channel BLOCKER IC50 7.40 IUPHAR

External reference:

IDSource
4020286 VUID
N0000148163 NUI
D03365 KEGG_DRUG
65-31-6 SECONDARY_CAS_RN
4018610 VANDF
4020286 VANDF
C0028040 UMLSCUI
CHEBI:17688 CHEBI
NCT PDB_CHEM_ID
CHEMBL3 ChEMBL_ID
DB00184 DRUGBANK_ID
D009538 MESH_DESCRIPTOR_UI
89594 PUBCHEM_CID
2585 IUPHAR_LIGAND_ID
6M3C89ZY6R UNII
1306106 RXNORM
11529 MMSL
5173 MMSL
5174 MMSL
72003 MMSL
d00316 MMSL
001770 NDDF
003575 NDDF
323283001 SNOMEDCT_US
68540007 SNOMEDCT_US
77544001 SNOMEDCT_US
D061485 MESH_DESCRIPTOR_UI
CHEMBL1201536 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5400 INHALANT 4 mg RESPIRATORY (INHALATION) NDA 29 sections
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5401 SPRAY, METERED 10 mg NASAL NDA 28 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0029 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0053 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0170 GUM, CHEWING 4 mg ORAL ANDA 15 sections
good sense nicotinemint HUMAN OTC DRUG LABEL 1 0113-0206 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0344 LOZENGE 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0422 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0456 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0532 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0704 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0713 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0734 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0749 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0761 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0854 GUM, CHEWING 4 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-0873 LOZENGE 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0957 LOZENGE 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-1125 LOZENGE 2 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-1190 LOZENGE 4 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-1352 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7007 LOZENGE 4 mg ORAL ANDA 14 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7008 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7029 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7124 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7170 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7190 LOZENGE 4 mg ORAL ANDA 15 sections
Basic Care nicotine HUMAN OTC DRUG LABEL 1 0113-7201 LOZENGE 2 mg ORAL ANDA 14 sections
Basic Care nicotine HUMAN OTC DRUG LABEL 1 0113-7203 LOZENGE 4 mg ORAL ANDA 14 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7344 LOZENGE 2 mg ORAL ANDA 15 sections